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Many  high  income  countries  increased  their  level  of patient  cost  sharing  between  2000
and 2010  as  one  component  of  their  policy  agenda  to  reduce  the  level  of  health  care  spend-
ing. We  use data  from  the  OECD,  European  Observatory,  and  country-speciﬁc  resources  to
analyze  trends  in  the UK,  Germany,  Japan,  France,  and the  United  States.  Some  forms  of
cost sharing—deductibles,  co-insurance,  or co-payments—increased  in all  these  countries,
with the  highest  rates  of  increase  occurring  in  the  pharmaceutical  sector.  In  spite  of higherost sharing
ut-of-pocket
eductibles
o-insurance
levels  of  cost-sharing,  out-of-pocket  spending  as  a percentage  of total  spending  remained
unchanged  in  most  of  these  countries  because  they  instituted  programs  to  protect  cer-
tain  categories  of  individuals  by creating  out-of-pocket  limits,  exempting  people  with
eases,  
e.
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. Introduction
One response to the increasing percentage of the
ross domestic product (GDP) being spent on health care
ector between 2000 and 2010 was that many OECD
ountries created or expanded cost sharing programs to
educe the demand for health care services, to reduce
oral hazard [1], or to promote appropriate utilization of
ealth care services [2,3]. In this paper, we focus on the
se of three different types of cost sharing: deductibles,
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co-insurance and co-payments. This article focuses on
changes in cost sharing in three large sectors of the health
care industry—pharmaceutical, outpatient and inpatient
services—and then examines some of the mechanisms
these countries have taken to protect vulnerable groups
from increases in cost sharing. We compare the programs
in France, Germany, Japan, the UK, and the United States.
These ﬁve high income countries represent more than half
of the populations in OECD countries2 in 2010 [4,5]. Also,
according to one health system classiﬁcation algorithm,
these countries use a variety of ﬁnancing systems includ-
ing: National Health Insurance, National Health Service,
Social Health Insurance and Mixed System [6].
Countries began this time period with different
Open access under CC BY-NC-SA license.approaches to cost sharing and their thinking evolved over
this time period. One reason their thinking evolved was
each country’s own experience with cost sharing; another
2 USA, Japan, Mexico, Germany, Turkey, France and UK were the
ﬁve countries with the largest population in the OECD during the
period 2000–2010.We did not include Turkey and Mexico because those
countries are not comparable on many indicators.
r CC BY-NC-SA license.
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reason was they compared their experience with other
similar countries. In this paper, we assemble health care
cost sharing experiences of these countries and compare
their evolution of cost sharing approaches and whom they
have chosen to protect from increasing levels of cost shar-
ing across the countries. The intention is to provide policy
makers with a mechanism to compare the cost sharing
approaches taken and the groups the various countries con-
sider most vulnerable. Countries can look at the interna-
tional experience for additional approaches to cost sharing.
To analyze the trends in the level of out-of-pocket
spending in these selected countries, we used OECD data
and used the OECD method of classiﬁcation known as a
“System of Health Accounts (SHA)” to deﬁne out-of-pocket
spending to include “cost sharing, self-medication and any
other expenditures directly paid by private households,
irrespective of whether the contact with the health care
system was established by referral or on the patient’s
own initiative” [7]. We  recognize that some of these
cost sharing policies were implemented in conjunction
with other policy changes; however, for purposes of this
analysis, we decided to focus simply on the cost sharing
arrangements and the protections from cost sharing that
have been implemented.
In 2000 these countries had adopted different
approaches to cost sharing; this paper examines three
main questions concerning the evolution of their cost
sharing programs from 2000 to 2010:
(1) What are the main changes in the level of cost sharing
in the three large sectors of the health care industry?
(2) What are the main mechanisms for protecting certain
vulnerable groups from increases in cost sharing?
(3) Are countries moving toward convergence in their
levels of cost sharing and mechanisms for protecting
vulnerable groups?
Policy makers can use this information to determine
where each country is on the spectrum of use of cost sharing
compared to other countries and also to compare the cate-
gories of people that are excluded from most cost sharing
provisions.
2. Methods
Data were obtained from the OECD, European Obser-
vatory, World Health Organization (WHO) reports, and
country-speciﬁc reports. The OECD health data presents
information on the percent of the GDP allocated to the
health sector, the share of revenues coming from private
and public insurance, out-of-pocket expenditures, pur-
chasing power parities, hospital bed days and hospital
lengths of stay [4,8,9]. These data was supplemented with
WHO  reports from 2000 to 2005 [10–12], WHO’s World
Health Reports, and the World Health Statistics from 2005
to 2010 [13]. The reports of the European Observatory were
used to identify recent changes in cost sharing and protec-
tions of vulnerable groups [14–16]. We  also reviewed spe-
ciﬁc regulations in certain countries [17–22]. All expendi-
tures were adjusted using purchasing power parities.
Because the U.S. health care system is so diverse with
so many different cost sharing arrangements, we  focusedlicy 112 (2013) 35– 44
the U.S. discussion on programmatic changes exclusively
on the Medicare program. Medicare is a federally funded
national program so it is most comparable to programs in
the other countries; however, Medicare only covers people
over age 65 or who  are disabled or have end stage renal
disease. We  used the Center for Medicare and Medicaid
Services website [18,22–24] to determine changes in cost
sharing covered by Medicare [18].
3. Results
3.1. Decade begins
The countries began this decade with varying
approaches to cost sharing. France and the UK began
this decade with lower levels of cost sharing than the other
selected countries. The U.S. health care system had varying
level of cost sharing in different insurance programs
ranging from virtually nothing in the Medicaid program
(program for the poor) to high-deductible health plans in
the private sector that required people to pay the ﬁrst sev-
eral thousand dollars before insurance coverage began. In
2000, the Medicare program did not even cover prescrip-
tion drugs for most Medicare beneﬁciaries. Germany’s
health system started 2000 with no co-insurance and
minimal co-payment for certain services. Japan’s health
system approach had the highest levels of co-insurance
compared to the other countries in 2000.
3.2. Trends in overall out-of-pocket spending
While these countries began the decade with varying
levels of out-of-pocket per capita spending on health care,
there was some convergence across the countries over the
decade. In 2010 the level of per capita out-of-pocket spend-
ing varied from a high of $970 in the U.S. to a low of $290
in France (Table 1). Between 2000 and 2010, the largest
percentage increase occurred in Germany (87%) and the
smallest percentage increase occurred in the U.S. (36%). The
percentage of health care resources spent out-of-pocket
declined in the UK and the U.S. and increased in the
other three countries. In all ﬁve countries, out-of-pocket
spending from 2000 to 2010 represented an increasing per-
centage of total household income, with the largest growth
in the percentage of household income spent out-of-pocket
in Germany (62.4%) and the least in Japan (20.3%).
We now turn our attention to cost sharing in the three
major areas of health care spending: pharmaceuticals,
inpatient, and outpatient sectors. While there was often
a general approach to cost sharing across the three sectors
in each country, there were also differences in approach
across the three sectors within each country. There were
also common approaches within each of the three sectors
across the countries.
3.3. Cost sharing and exemptions for pharmaceuticalsCountries adopted different approaches for con-
trolling pharmaceutical expenditures including the
following: offering incentives for using generic medicines
[14,15], promoting the use of over-the-counter medicines
Z. Hossein, A. Gerard / Health Policy 112 (2013) 35– 44 37
Table 1
Comparing changes in out-of-pocket payments in selected countries: 2000–2010.
Year Japan France Germany UK USAb
Per capita total current health care spendinga
2000 $1.898 $2.484 $2573 $1751 $4571
2010  $2979c $3835 $4187 $3253 $7910
Percent increase 2000–2010 57.0% 54.4% 62.7% 85.8% 73.1%
Per capita out-of-pocket spending
2000 $303 $181 $306 $209 $715
2010  $485c $290 $571 $306 $970
Percent increase 2000–2010 60.1% 60.2% 86.6% 46.4% 35.7%
Out-of-pocket as percent of total current expenditures
2000 16.0% 7.3% 11.9% 11.9% 15.6%
2010  16.3% 7.6% 13.6% 9.4% 12.3%
Out-of-pocket spending as a percent of household income
2000 1.7% 0.9% 1.5% 1.0% 2.4%
2010  2.1% 1.2% 2.4% 1.3% 3.3%
Percent increase 2000–2010 20.3% 34.2% 62.4% 29.3% 38.6%
Source: OECD Health Data, Database: Health Expenditure and Financing; Access: 02 May  2013: http://stats.oecd.org.
a Based on International Classiﬁcation for Health Accounts. Total Current Health Expenditure is divided into 8 categories: (HC.1. Curative care; HC.2.
Rehabilitation care; HC.3. Long-term nursing care; HC.4. Ancillary services; HC.5. Medical goods dispensed to out-patients; HC.6. Preventions and public
health; HC.7. Administration and health insurance; HC 8 is not recorded; HC.9. Expenditure on services not allocated by function. Total current expenditure
will  be the total amount for all expenditure categories (HC1–HC9). Adding investment (gross capital formulation in health) becomes total expenditure on
health  [A System of Health Accounts (SHA 2011)].
b The analysis for US policy changes covers only the Medicare program, but values reported here for the US are for the whole US population. Medicare
Expenditure covered 17.4% and 21.3% of Total Current Expenditure for 2000 and 2010 [Center for Medicare and Medicaid Services, Ofﬁce of the Actuary,
National Health Statistics Group; NHI; 1960–2011].
[
p
d
a
y
c
h
h
r
s
o
a
h
c
T
T
C
Sc Last data available for Japan: 2009.
d Values reported are adjusted for Purchasing Power Parity (PPP) [5].
14,16], decreasing the number of drugs on the national
harmaceutical list [14], encouraging the use of generic
rugs [14–16,25], increasing the use of formularies [16,26],
nd evaluating certain drugs using cost-effectiveness anal-
sis [27]. These policies often interact with cost sharing
hanges and are generally considered part of a compre-
ensive package for pharmaceutical reform. In this section,
owever, we only focus on the cost sharing component,
ecognizing that other policies could interact with cost
haring.
Between 2000 and 2010, the most rapid increase in
verall pharmaceutical spending occurred in the U.S. (82%)
nd the slowest in the UK (42%). Japan (21.2%) spent the
ighest percentage on pharmaceuticals and the lowest per-
entage occurred in the U.S. (11.9%) in 2010 (Table 2).
he percentages spent on pharmaceuticals were generally
able 2
omparing pharmaceutical expenditures in selected countries: 2000–2010.
Japan France 
Per capita pharmaceutical expenditures (PPP)a
2000 $364 $420 
2010  $630c $634 
%  Change 73.1% 51.0% 
%  Pharmaceutical expenditures as a percent of total current health expenditure
2000 19.2% 16.9% 
2010  21.2%e 16.5% 
ource: OECD Heath Data, last updated 10 August 2012: http://www.oecd.org/he
a Please see foonote ‘a’ in Table 1.
b The analysis for US policy changes covers only Medicare, but here values repo
c Japan, 2009.
d UK, 2008.
e Percentage reported changes between 2000 and 2009.
f Percentage reported changes between 2000 and 2008.
g Values reported are adjusted for Purchasing Power Parity (PPP) [5].stable in the 10-year period. Countries adopted different
approaches toward cost sharing and protecting different
individuals from cost sharing during the period.
3.3.1. France
Beginning in January 2008, patients in France paid a
ﬁxed co-payment of D 0.50 for each prescription drug with
an annual ceiling of D 50 [28]. France also increased the
level of cost sharing by 15–35%. The level of increase var-
ied by clinical criteria developed by the Service Medical
Rendu (SMR) and Amélioration du Service Médical Rendu
(ASMR) [14,28]. Based on SMR, drugs are categorized into
4 categories: major, moderate, low, and insufﬁcient. The
Transparency Committee of the French National Health
Authority focused on risk or beneﬁt ratio for evaluating
the actual medical beneﬁt and rated each drug from low
Germany UK USb
$362 $260 $540
$640 $369d $983
76.8% 41.9% 82.0%
s
14.1% 14.9% 11.8%
15.3%f 11.3% 12.4%
alth/health-systems/oecdhealthdata2012.htm.
rted for US are for the whole US population.
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to major. There are ﬁve designed criteria: “effectiveness
of drugs and possible side-effects, available alternative
therapies, seriousness of condition, curative, preventive
or symptomatic priorities of the drugs, and importance
in terms of public health” [14,28]. Based on the ASMR,
drugs are classiﬁed into 5 levels with the ﬁrst level being
a major therapeutic advance, and then important, moder-
ate and minor improvement; the last level is absence of
improvement but favorable opinion for registration on the
reimbursable drugs list [28]. The pathology of the illness is
categorized into two categories: serious and non-serious
illness. For drugs in the ﬁrst category of SMR  the reim-
bursement for serious illness is 65% of the cost and for
non-serious illness, 35%; for the other categories, contri-
bution for the other groups are 65%, 85% and 100% [14,28].
Between 2000 and 2006 drugs covered under NHI (National
Health Insurance) were re-evaluated by considering Thera-
peutic Value (SMR), and more than hundreds of drugs were
removed from the positive list during the evaluation pro-
cesses because they did not meet the SMR  criteria. In 2010
the rate of cost sharing for 171 drugs with low SMR declined
from 35% to 15% [14].
France protected certain people from this increased
cost sharing by including 100% reimbursement for non-
substitutable or expensive prescription drugs and a cap
on annual out-of-pocket payments at D 50 [28]. Children
under 16 years of age and patients with complementary
universal health coverage (Couverture Maladie Universelle
Complémentaire, CMU-C) were excluded from any cost
sharing3 [28]. France also protected people with 30 deﬁned
chronic diseases. Those patients’ protection will not be
subject of cost sharing if they visited by the physician in
sector 14 [29]. Several other groups are also protected from
cost sharing: people with work-related accidents, pregnant
women after their 5th month of pregnancy, disabled chil-
dren, and pensioners [14].
3.3.2. Germany
Germany increased the level of cost sharing over this
time period and increased the ﬁxed co-payment from D 3
in 2000 [9] to D 5–10 in 2010 [30]. Germany introduced
two main reforms—in 2004, The Statutory Health Insurance
(SHI) Modernization Act (GMG) and in 2007 the Statutory
Health Insurance Competition Strengthening Act (GKV-
WSG)—that increased the co-payment for drugs [31]. The
2004 reform increased cost sharing to 5–10% of the refer-
ence price [32] and in 2008 it standardized to 10% of the
cost of drugs priced between D 50 ($66) and D 100 ($130)
[33] with a minimum of D 5 ($6.5) and a maximum of D 10
3 Since 2000, complementary universal health coverage has been
offered on a voluntary basis to protect certain socioeconomic groups from
the consequences of co-insurance. This plan covers approximately 7% of
the population [14].
4 Based on the contract agreements between National Health Insur-
ance and private physicians, physicians are divided into two main sectors:
In  sector 1, physicians are under contract and paid fee-for-service and
receive pension and sickness beneﬁts; in sector 2, physicians can set their
own  fees that may  exceed the ofﬁcial fee schedule, but the physicians are
not eligible for sickness and pension beneﬁts. More than 96% of physicians
are in sector 1 or 2. There is a small percentage of physicians who are not
in  sectors 1 or 2 [29].licy 112 (2013) 35– 44
($13) per prescription [34,35], plus costs above a reference
price (about 7% of drugs) [30,35]. Drugs priced 30% below
their reference price were exempted from co-payments
[36].
Several regulations were designed to protect certain
individuals from the cost-sharing including exempting
children less than 18 years of age, low-income groups,
and individuals with chronic diseases. Germany also estab-
lished limits on out-of-pocket payments in 2004. People
who  do not have chronic conditions do not have to pay
more than 2% of the gross annual household income; for
people with chronic diseases, this amount is 1% [25,31].
3.3.3. Japan
Between 2002 and 2006, reforms in Japan’s health sys-
tem raised the level of co-payment to 30% [37]. The current
rate remained at 30% for most individuals; however, for
children less than 7 years of age, the co-payment was
reduced to 20%. People who  are ≥70 years of age and
have incomes less than the average worker pay a 10% co-
payment. The level of cost sharing is a combination of
co-payment and includes a consideration of the number
of drugs prescribed: zero for one drug and $0.85 for six or
more drugs prescribed for drugs that are taken internally
and $0.4 (for one) $1.2 (for three) prescribed for topical
use [9]. In addition, all insurance plans have a monthly
out-of-pocket ceiling5 [33] of $1903 (150,000 yen) for
high-income people and $449 (35,400 yen) for low-income
people; above this ceiling only 1% of co-payment applied.
Low-income people covered by the Livelihood Protection
program do not pay co-insurance [15].
3.3.4. United Kingdom
In 2000 only 14% of prescriptions were subject to cost
sharing [16,38]. In 2000 [9] a ﬁxed amount for these drugs
was  $9 per prescription, which increased to $11.3 in 2010
(£7.2 per item from 1 April 2010). The percentage of pre-
scriptions subject to cost sharing has declined and in 2009
only 6% of all prescription items were subject to cost
sharing In spite of this increased level of coverage, out-of-
pocket payment per capita increased from £133 in 1998 to
£230 in 2008 (72% growth) [18].
Although the UK has a limited number of drugs sub-
ject to cost sharing, the UK still [16] protects around 50%
of the population from cost sharing, including children
under 16 years of age, full-time students 16–19 years,
pregnant women and women who  have given birth dur-
ing the past 12 months, people ≥60 years of age, people
with speciﬁc medical conditions (e.g., cancers and long-
term conditions), low-income groups, and those who use a
large number of drugs [39,40].
3.3.5. United States
Because the U.S. has so many different insurance sys-
tems, we focused just on the Medicare program. Medicare
covers people over age 65, people with disabilities and
those with end stage renal disease. It should be recognized
that most Medicare beneﬁciaries purchase supplemental
5 This out-of-pocket ceiling applies generally not just for drugs.
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edicare coverage known as Medigap which pays some or
ll of the cost sharing [41,42]. There are twelve standard-
zed individual polices, labeled A through L, that private
nsurers can offer to Medicare beneﬁciaries. The ratio-
ale for having standardized policies is to make it easier
or Medicare beneﬁciaries to compare Medigap plans. The
lans differ on the scope of the beneﬁt package they
ffer, with some of the plans covering all the cost sharing
47].
The Medicare program added prescription drug cover-
ge in 2003 with implementation occurring in 2005 [18].
edicare prescription drug coverage is provided by pri-
ate health plans that can vary their level of cost sharing.
here is, however, a standard plan and that is what we
ill discuss. The standard prescription drug beneﬁt in the
edicare program is shown in Fig. 1 [23]. There are three
evels of cost sharing depending on how much the Medi-
are beneﬁciary spent on drugs during the year. There is
n annual deductible of $310. Cost sharing begins after
he deductible is paid and begins at 25%, goes to 100%
no coverage), and then reverts back to 5%. The Patient
rotection and Affordable Care Act [43] revises the cost
haring arrangements and over the 2011–2020 period the
ost sharing will become 25% for all drugs until the out-
f-pocket threshold is reached, when it becomes 5% [24].
nlike most other countries, Medicare does not have an
ut-of-pocket cap. Low-income individuals do not have to
ay the cost sharing amounts if they qualify for the Medic-
id program [18,23,24].t sharing in 2010.
3.4. Cost sharing and exemptions for inpatient services
Countries have adopted many different approaches
for controlling inpatient spending: developing pay-for-
performance [14,15,25], payment by results [16], control-
ling the rate of readmissions; reducing acute care capacity,
developing day surgery centers and home hospitalization,
and moving toward DRG based prospective payment sys-
tems [14,15,25]. Some countries have expanded the use
of private sector hospitals [16] or used referral [16,25], or
gate-keeping systems [16] to control utilization of inpa-
tient services [14,25]. In this section, however, we only
focus on the cost sharing provisions.
Table 3 shows changes in out-of-pocket spending for
hospitals. Per capita spending on hospitals was  signiﬁ-
cantly higher in the U.S. but out-of-pocket spending was
within the range of the other countries. Japan had the high-
est out-of-pocket spending in both 2000 and 2010.
3.4.1. France
France maintained the level of co-insurance for inpa-
tient services at 20% from 2000 to 2010, and increased
the co-payment from D 10.67 in 2000 [26] to D 16–D 20 in
2010 [14]. France protected several groups from cost shar-
ing for hospital services; people with 30 speciﬁc long-term
illnesses as well as other rare diseases that are not listed
in the 30 disease list are excluded from cost sharing. There
is also no cost sharing after the 31st day of hospitalization.
Pregnant women hospitalized during the last four months
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Table  3
Hospital expendituresa and out-of-pocket payments in selected countries: 2000–2010.
Year Japan France Germany UKc USAd
Per capita hospital expenditure (PPP)b
2000 $967 $898 $800 NA $1473
2010  $1431d $1357 $1245 NA $2634
%  Change 48.0% 51.1% 55.6% NA 78.8%
Per-capita out-of-pocket payment (PPPb)
2000 $93 $24e $20 NA $58e
2010 $164f $37 $37 NA $84
%  Change 76.3% 54.2% 85.0% NA 44.8%
Source: OECD Heath Data, last updated 10 August 2012: OECD Health Data, Database: Health Expenditure and Financing; Access: 02 May 2013:
http://stats.oecd.org.
a Hospital expenditure covered value of health services provided by hospitals based on OECD SHA Manual HP.1. Categories of health care provider costs
covered hospital expenditures [A System of Health Accounts (SHA 2011)].
b Purchasing power parity (PPP).
c The UK does not report these data to the OECD.
ues repod The analysis for US policy changes covers only Medicare, but here val
e France, 2003; USA, 2003.
f Japan, 2009.
of pregnancy or 12 days after childbirth do not pay any cost
sharing [14]. Low-income people covered by the Universal
Health Insurance Law, disabled children and pensioners are
also excluded [14]. In 2006 people were required to pay a
ﬂat rate of D 18 for expensive care such as magnetic res-
onance imaging (MRI) and some surgical procedures with
a relative weight higher than an appendectomy, but these
people did not need to pay this ﬂat rate and, if they pur-
chased voluntary health insurance, it would cover the ﬂat
rate. Services with tariff over D 91 (any procedure with a
relative weight higher than an appendectomy) were not
subject to cost sharing [14].
3.4.2. Germany
In 2010 Germany increased the level of cost shar-
ing from D 3 in 2000 [9] to D 10 per inpatient day
[25,30]. Germany has protected the following people from
increased cost sharing: co-payment for hospitalizations
after 28 days [44], pregnant women, children less than 18
years of age [44], and individuals are excluded from cost
sharing if they spent annually more than 2% of their gross
household income on cost sharing, or 1% of their gross
household income if they have a serious chronic disease
[25] or lost 60% of their capacity to work [25,44]. Certain
chronic diseases as deﬁned by the Ministry of Health [30]
also have reduced cost sharing.
3.4.3. Japan
Japan increased the level of cost sharing from 20% in
2000 to 30% in 2010 [15]. Japan has protected certain
people from increased cost sharing by exempting certain
categories of people. Since 2003, people ≥75 years and chil-
dren below 3 years had their rate lowered to 20%. The rate is
10% for low and moderate income people ≥75 years of age
and 20% for high-income persons above age 75 [15]. Rates
for people 65–74 increased to 30% in 2008 and cost shar-
ing was reduced for certain low-income individuals [15].
For example, Japan excludes people from cost sharing if
they have one of 56 chronic diseases and who participate
in research studies [19].rted for US are for the whole US population.
3.4.4. United Kingdom
Almost all of the covered inpatient health services oper-
ate without cost sharing [30]. The NHS also covers services
that limit access to necessary medical care. For example,
coverage without cost sharing may  be available for trav-
els to receive consultant services under coverage of NHS,
depending on age or medical need [16,45].
3.4.5. United States
In the Medicare program, the level of cost sharing has
continually increased with the hospital deductible increas-
ing from $776 in 2000 to $1112 in 2010 [18]. Co-insurance
after 60 days and before 90 days increased from $194/day in
2000 to $275/day in 2010, and co-insurance for 60 lifetime
reserve days increased from $388/day to $550/day [22].
The federal government has many different pro-
grams for protecting beneﬁciaries from these increases
and almost 90% of Medicare beneﬁciaries have some
form of public or private coverage that covers their
cost sharing [46]. These include Government Programs
(Medicaid/QMB/SLMB), Group Retirement Policies (Non-
Standardized), Non-Standardized Individual Medigap Poli-
cies, and Standardized Individual Medigap Policies [41,42].
In the standardized individual Medigap polices there
is variation in what out-of-pocket services are covered.
Plan A contains only basic beneﬁts and other plans con-
tain the basic beneﬁts and one or more additional beneﬁts.
For example, plan K covers all cost sharing for hospital ser-
vices once an individual has reached annual out-of-pocket
limit expenditures of $4620 in 2010 [42].
There are several exemptions for low-income groups; if
the person has Medicaid coverage, the Medicaid program
covers the co-insurance amount. The states determine who
is eligible for Medicaid coverage so the level of protection
varies from state to state. The Tax Relief and Health Care
Act of 2006 (TRHCA) limits the cost sharing and premium
to 5% of family income for Medicaid beneﬁciaries [48].3.5. Cost sharing and for providers of ambulatory care
Countries have adopted different mechanisms for
decreasing the cost of ambulatory care. These include
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Table 4
Comparing per capita ambulatory care expendituresa in selected countries: 2000–2010.
Japan France Germany UKc USA
Per capita ambulatory care expendituresb
2000 $549 $677 $756 NA $1712
2010  $810d $1082 $1278 NA $2851
%  Change 47.5% 59.8% 69.0% NA 66.5%
Per  capita out-of-pocket payment (PPPa)
2000 $93 $71e $73 NA $329f
2010 $136g $110 $167 NA $396
%  Change 46.2% 54.9% 128.8% NA 20.4%
Source: OECD Heath Data, last updated 10 August 2012: OECD Health Data, Database: Health Expenditure and Financing; Access: 02 May  2013:
http://stats.oecd.org.
a Values reported by international dollar (Purchasing power parity; PPP).
b Based on OECD SHA Manual, these institutions provide health care services directly to out-patients who do not require in-patient services. Pediatric
and  geriatric conditions except for services provided by health practitioners in ambulatory health care [A System of Health Accounts (SHA 2011)].
c The UK does not report these data to the OECD.
d Japan, 2009.
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eveloping pay-for-performance systems [14,25] which
romote direct negotiations between providers and insur-
rs [14,15,25], designating certain doctors as the ﬁrst point
f contact in health networks [14]; using patient-centered
edical homes [30]; implementing lifelong learning for
eneral practitioners (GPs) [14]; paying bonuses for meet-
ng speciﬁed performance targets [16]; using referral
ystems; having waiting time for controlling access to
pecialist services [16,25]; developing highly specialized
ospital outpatient clinics; providing ambulatory surgery
25]; and substituting nurses for physicians to provide cer-
ain services [4,14–16,25]. We  will again focus only on cost
haring provisions in these selected countries.
In 2010, the level of per capita out-of-pocket spending
or ambulatory care varied from $396 in the US and $110
n France (Table 4). Between 2000 and 2010, the largest
nnual percentage increase occurred in Germany (12.9%)
nd the smallest percentage increase occurred in the US
3.4%). Table 4 provides the changes in outpatient services
etween 2000 and 2010, based on the System of Health
ccounts (SHA) classiﬁcation for outpatient services that
ncludes physician’s private ofﬁces, hospital out-patient
enters or ambulatory-care centers.
.5.1. France
France did not change the co-insurance rate for GPs and
pecialists from 2000 to 2010; it remained at 30%, but it
dded a ﬂat rate co-payment of D 18 in 2006 [14,30]. Since
005, on every physician visit, biological test, or radiology
rocedure, D 1 is charged with a ceiling of D 4 per day and
 50 per year. In early 2008 patients requiring transporta-
ion for ancillary care services paid D 2 for the services up
o D 50 for the year and after that no payment was needed
14].
France has protected certain people by exempting cer-
ain individuals from cost sharing. Exams conducted during
regnancy, ﬂu vaccines for people over 65 years, MMR  vac-
ines for children less than 13 years of age and some forms
f cancer screening are exempted from cost sharing [44].
here is also a maximum out-of-pocket payment for out-
atient services provided by doctors, medical auxiliaries,or laboratories. If the tariff is more than D 91, there is no
cost sharing [14]. In recent years approximately 88% of the
French population purchases Voluntary Health Insurance
(VHI). This supplemental insurance coverage ﬁlls the gap
between what NHI pays and the total bill or pays for some
medical goods and services that are not covered or have
poor coverage under NHI. These supplemental insurances
usually provide full coverage for patient’s copayment for
medical tests, health professionals’ up to ofﬁcial NHI tar-
iff [14,22]. Because of VHI most of coinsurance paid by
patients is reimbursed by the supplemental health insur-
ance.
3.5.2. Germany
The reform in 2004 (Statutory Health Insurance Mod-
ernization Act [GMG]) introduced D 10 user fees for ﬁrst
visits to an outpatient provider and for visits for any other
physician in the same quarter except by referral [31].
Germany has protected certain people from this increased
cost sharing including: pregnant women, children and ado-
lescents up to 18 years of age [44]. Certain services are
also exempt from cost sharing for speciﬁc services such as
preventive care [31,44].
3.5.3. Japan
Japan increased the level of cost sharing from 20% in
2000 to 30% in 2010 for all ambulatory services [15]. Japan
protected certain people from these increases: Children
less than 3 years of age pay only a 10% co-payment; peo-
ple over 74 years of age have co-insurance of 10% for
low- and middle-income individuals and 20% for high-
income individuals. There is also a maximum of 10,000 yen
(approximately US$127) per month for patients undergo-
ing renal dialysis [15].
3.5.4. United Kingdom
Although most ambulatory services are free-of-charge,some services are not covered by the NHS [16]. For some
of these services there is ﬁnancial assistance for some
individuals[16]. For example, ophthalmic services are not
available in NHS facilities, but vision tests, cost of glasses
42 Z. Hossein, A. Gerard / Health Policy 112 (2013) 35– 44
Table  5
Comparing groups excluded from cost sharing payments in selected countries.
Country Pharmaceuticals Outpatient care Inpatient care
France (a) Cap on annual out-of-pocket payments
at D 50
(a) Pregnant women for exams during
pregnancy
(a) Cap for payment after 31st day of
hospitalization
(b)  Children under 16 years (b) Flu vaccines for people over 65 years (b) Pregnant woman in last 4 months of
pregnancy
(c)  Patients with complementary universal
health coverage
(c) MMR  vaccines for children less than 13
years
(c) Low-income people covered by
Universal Health Insurance Law
(d)  People with 30 deﬁned chronic diseases (d) Some forms of cancer screening (d) Disabled children and pensioners
(e)  People with work related accidents (e) Cap for tariffs more than $91 (e) Services with tariff over D 91
(f)  Pregnant women after their 5th month
of pregnancy
(f) More than 88% of people have Voluntary
Health Insurance (VHI). VHI provides
coverage by ﬁlling gap between NHI and
overall cost
(f) VHI covers all of the co-payments
(g)  Disabled children and pensioners
Germany (a) Cap on gross annual household income
1% for people with chronic disease and 2%
for all other
(a) Pregnant women (a) Cap for payment after 28th day of
hospitalization
(b)  Children less than 18 years (b) Children and adolescents up to 18 years (b) Pregnant women
(b)  Low-income groups (c) Certain groups for preventive care (c) Children less than 18 years old
(c)  Individuals with chronic diseases (d) Cap on gross annual household income
1% for people with chronic disease and 2%
for all other or people who lost 60% of their
capacity to work
(f) Certain chronic diseases
Japan (a) Cap based on income (a) 10% less
co-payment for children under 7 years old
(a) Children less than 3 years pay 10% All of the groups need to pay co-payment.
Certain groups have lower coinsurance
amounts:
(b)  20% less co-payment for elderly people
with 70 years old and over
(b) People over 74 years old pay 10% if they
are  in low-income level and 20% in
high-income level
(a) People 75 years old or above 10%
(c)  Considering the co-payment and
number of drug for cost sharing: Zero for
one drug, $0.85 for 6 and more certain
categories of drugs, $0.4 (one) and 1.2
(three) for other categories of drugs
(c) Cap 10,000 yen (US$127) per month for
renal diseases
(b) Children below 3 years old 10%
(c) Low and moderate income people with
75  years or above 10% and high income
persons above age 75–20%
(d) People with 56 chronic diseases that
participate in research studies
UK  86% of drugs are free of charge. For the
other drugs the following groups are
excluded:
Most ambulatory services are
free-of-charge. For services not covered by
NHS individuals requiring a vision test,
cost of glasses and contact lenses who are
in  these categories are covered
(a) Free-of-charge in point of service plans
in NHS centers
(a)  Children under 16 years (a) Children under 16 years full-time
students 16–19 years, people aged 60
years and older, low-income groups,
people with diabetes or people who have
or at risk of glaucoma
(b) Full time students 16–19 years
(c) Pregnant women
(d) Women who have given birth during
the past 12 months.
(e) People aged 60 years and above
(f) People with speciﬁc medical conditions
(g) Low-income groups
(h) People with large number of drugs
USA (a) Cost sharing decreased to 5% after
$6440 cap
(a) Medigap provides some or all of the
cost sharing based on the plan
(a) Low-income groups with Medicaid
eligibility under the state rules
(b)  Low-income groups eligible for
Medicaid
(b) Low-income eligible people for
Medicaid
(b) Some Medigap plans cover some or all
of the cost sharing
(c)  Some of the privately purchased
Medigap plans (plans G and J) cover all of
the  out-of-pocket payments
(c) Children under age 18 are covered by
Medicaid except up to 20% cost sharing for
some drugs
(d) Cap for cost sharing and premium for
5% of family income
Source: OECD, WHO, Medicare, European Observatory sites.
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nd contact lenses for children under 16 years of age, full-
ime students 16–19 years of age, people ≥60 years of age,
ow-income groups, people with diabetes, or people who
ave or at risk of glaucoma are covered [16,30].
.5.5. United States
In the Medicare program the level of cost sharing has
ot increased, but the deductible has increased from $100
n 2000 to $162 in 2010 [18]. As mentioned earlier, many
eople purchase Medigap coverage privately or get pub-
ic assistance that pays their cost sharing. In the U.S.,
ow-income people covered by the Medicaid program are
enerally exempt from Medicare cost sharing; however,
he rules vary by state.
. Discussion
All of the selected countries have experienced increases
n the level of cost sharing for one, two, or all three ser-
ices during the 2000–2010 period. At the same time, the
ercentage of total out-of-pocket spending as a percent-
ge of total health expenditures has declined. One main
eason is that the countries have eliminated cost sharing
or some speciﬁc groups. While each country has taken its
pproach, there appears to be similar approaches to cost
haring, similar approaches to protecting people from cost
haring, and a general trend toward convergence of the cost
haring systems.
Pharmaceutical services: There is considerable common-
lity across the countries. In all of selected countries the
evels of cost sharing have increased, with ﬁxed payment
or each prescription the most common way for increas-
ng the level of cost sharing. Clinical effectiveness criteria
re commonly used for determining the level of cost shar-
ng [33] or making the person pay entirely out-of-pocket
or inefﬁcient drugs [49]. Countries have protected certain
eople from high drug costs by capping their out-of-pocket
ayments [14,15,35] or by exempting or reducing the level
f cost sharing for low-income groups, children, people
ith speciﬁc chronic diseases, pregnant women, and older
eople [14–16,18,25].
Inpatient services: In each of the selected countries
except for the UK, which still does not have any cost shar-
ng), cost sharing for inpatient services increased during
he 2000–2010 period. Generally, the level of cost shar-
ng for hospital services represents a small percentage of
he total cost compared to other health care services. The
ost common approach is protecting individuals from any
ype of hospital cost sharing to exclude low-income per-
ons, the elderly, and people with selected chronic diseases,
regnant women, and children. Another approach is to cap
ut-of-pocket payments and reduce cost sharing for long-
erm hospital stays.
Outpatient care: In all of the selected countries, cost
haring for ambulatory costs increased from 2000 to 2010,
ith increasing the co-payment rate or deductibles as the
ost common way of implementing this change. Countries
ave tried to protect special groups from this increased cost
haring by deﬁning out-of-pocket maximums or by pro-
ecting certain deﬁned groups of people. The most commonlicy 112 (2013) 35– 44 43
exclusions are children, people in certain age bands, and
pregnant women.
4.1. Are countries moving toward convergence?
In Table 5 we compared all of exclusions for these three
health expenditure sub-groups in the selected countries.
While the countries began the 21st century with very
different approaches to cost sharing, they are converging
both in their approaches to cost sharing and their protec-
tion for people from cost sharing. While most counties are
increasing the level of cost sharing, the highest rates of
increase tend to be in countries that began the decade with
the lowest rates of cost sharing. However, there is only min-
imal convergence on the percentage of the total bill that a
person has to pay or exactly how cost sharing should be
structured. Each country seems to retain their own philos-
ophy about cost sharing in spite of a general approach of
increasing the level of cost sharing. There is considerably
more consensus on who should be excluded from cost shar-
ing. The groups most commonly excluded from cost sharing
include people with chronic conditions, people in certain
age groups, low-income groups, and pregnant women.
4.1.1. Implications for policy
When out-of-pocket spending increased during the
2000–2010 period, policy makers initiated plans to pro-
tect vulnerable groups or services commonly used by
these groups. Among international policymakers, spend-
ing more than 10% [50] of total expenditures on health
care is often considered as a threshold for catastrophic
payment. Countries should examine what other countries
are doing in terms of cost sharing arrangements and pro-
tections. Countries need to evaluate their level of cost
sharing in relation to their overall health care programs
and how they are organized in relation to other industrial-
ized countries. Countries with limited cost sharing should
examine whether certain types of cost sharing could be
increased without adversely impacting access. This needs
to be done in conjunction with efforts to protect certain
groups that may  have greater levels of ﬁnancial burden or
are more likely to use health care services because of medi-
cal need. Countries can learn from the experiences of other
countries while still maintaining their own  unique health
care systems.
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